The results of this study clearly demonstrate that prophylactic use of ivermectin must be initiated immediately for people in high risk categories in the United States and worldwide. This includes individuals with one or more co-morbidities and the middle aged/elderly. Our “design-to-fail” government funded clinical trials for early treatment and governmental obstructionism regarding life saving treatments to patients must end now.
